Follow Forum_Psych on Twitter

Display results as :

Rechercher Advanced Search

We have 222 registered users
The newest registered user is raheelmemon

Our users have posted a total of 1140 messages in 613 subjects
If you are seeing this, you have attempted to link to the UpToDate widget but are experiencing a problem. Please visit UpToDate for more information.

Evidence-Based Guideline: Treatment of Tardive Syndromes

View previous topic View next topic Go down

Evidence-Based Guideline: Treatment of Tardive Syndromes

Post  Admin on Tue Sep 10, 2013 9:23 pm

Evidence-Based Guideline: Treatment of Tardive Syndromes
Report of the Guideline Development Subcommittee of the
American Academy of Neurology

This information is current as of July 29, 2013

To make evidence-based recommendations regarding management of tardive syndromes (TDS), including tardive dyskinesias (TDD), by addressing 5 questions:
1) Is withdrawal of dopamine receptor blocking agents (DRBAs) an effective TDS treatment?
2) Does switching from typical to atypical DRBAs reduce TDS symptoms?
3) What is the efficacy of pharmacologic agents in treating TDS?
4) Do patients with TDS benefit from chemodenervation with botulinum toxin?
5) Do patients with TDS benefit from surgical therapy?

Results and recommendations:

- Clonazepam probably improves TDD and Ginkgo Biloba probably improves TDS (both Level B); both should be considered as treatment.
- Risperidone may improve TDS but cannot be recommended as treatment because neuroleptics may cause TDS despite masking symptoms.
- Amantadine and Tetrabenazine might be considered as TDS treatment (Level C).
- Diltiazem should not be considered as TDD treatment (Level B);
- Galantamine and Eicosapentaenoic acid may not be considered as treatment (Level C).
- Data are insufficient to support or refute use of acetazolamide, bromocriptine, thiamine, baclofen, vitamin E, vitamin B6, selegiline, clozapine, olanzapine, melatonin, nifedipine, fluperlapine, sulpiride, flupenthixol, thiopropazate, haloperidol, levetiracetam, quetiapine, ziprasidone, sertindole, aripiprazole, buspirone, yi-gan san, biperiden discontinuation, botulinum toxin type A, electroconvulsive therapy, a-methyldopa, reserpine, and pallidal deep brain stimulation as TDS treatments (Level U).
- Data are insufficient to support or refute TDS treatment by withdrawing causative agents or switching from typical to atypical DRBA (Level U).

Click on to post your comments

Posts : 948
Points : 2102
Reputation : 0
Join date : 2011-02-19
Location : Philadelphia

Back to top Go down

View previous topic View next topic Back to top

- Similar topics

Permissions in this forum:
You cannot reply to topics in this forum